查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861444

性行為感染傳染病檢測市場按檢測類型、最終用戶、產品、技術、通路、疾病類型和檢體類型分類－2025-2032年全球預測

STD Testing Market by Test Type, End User, Product, Technology, Distribution Channel, Disease Type, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，性行為感染檢測市場規模將達到 160.3 億美元，複合年成長率為 6.11%。

關鍵市場統計數據
基準年 2024 99.7億美元
預計年份：2025年 105.8億美元
預測年份 2032 160.3億美元
複合年成長率 (%) 6.11%

權威深入剖析當前性行為感染檢測格局，探討創新、獲取壓力和不斷演變的醫療服務模式如何影響這一格局。

隨著技術進步、政策重點的轉變以及醫療服務模式的演變，性傳染性行為感染）檢測領域正經歷著快速且持續的變革。公共衛生計畫、臨床實驗室和照護現場機構都在積極應對日益成長的對更快、更準確、更便捷診斷的需求，同時也面臨著諸如社會污名、報銷不均以及法規環境波動等持續存在的障礙。這些矛盾正在改變從集中式參考實驗室到分散式照護現場機構等各種場所的檢測方法的開發、檢驗和實施方式。

診斷技術開發人員和醫療系統正優先推進能夠加快檢測速度、擴大非侵入性採樣範圍以及實現多重病原體檢測的創新，以簡化臨床決策流程。同時，數位化醫療整合和軟體驅動的工作流程正在改善數據收集、報告和患者照護協調。因此，價值鏈上的各相關人員越來越關注互通性、品質保證以及在各種臨床和社區環境中推廣新型檢測方法的可行性。

為了因應這種環境，領導者必須結合營運實際情況和監管限制來解讀技術進步，同時確保公平取得服務。以下章節將深入探討變革性變化、關稅相關影響、市場細分洞察以及區域性考量，這些內容全面說明了當前性性行為感染檢測的現狀。

分子診斷、非侵入性採樣、數位整合和分銷模式的創新如何重塑性傳染病檢測服務和臨床決策

該領域正經歷多重變革，這些變革正在改變臨床路徑、供應鏈和病患體驗。首先，分子診斷正透過簡化的工作流程和強大的檢體到結果平台，從專業實驗室轉移到更貼近患者的場所轉移，從而利用核酸擴增技術實現更早、更可靠的檢測。同時，等溫擴增技術的進步和橫向流動化驗化學方法的改進，正在縮小快速檢測和實驗室檢測之間的性能差距，為即時決策提供了更多選擇。

其次，唾液和自採拭子等非侵入性檢體類型的擴展降低了檢測門檻，使得在傳統臨床環境之外進行廣泛篩檢成為可能。同時，支援遠距結果交付、病患追蹤和電子病例報告的軟體和服務也促進了這一轉變，從而建立了更一體化的醫療服務路徑。第三，隨著製造商和經銷商採用全通路策略，分銷和採購管道正在多元化發展。這些策略包括線上平台和分銷網路直接向社區組織和家庭檢測消費者銷售產品。

最後，監管現代化和公共衛生優先事項正在推動適應性研究設計，並加快臨床檢驗檢測的核准流程。同時，對抗菌素抗藥性日益成長的關注凸顯了診斷指南治療選擇的必要性。總而言之，這些變化需要研發人員、實驗室和衛生部門協調應對，以確保診斷效能、公平取得和檢測專案的永續性。

評估2025年關稅調整對診斷設備、套件以及整個檢測生態系中最終用戶的供應鏈和採購的累積影響。

2025年推出的貿易政策變化對支持性傳染感染（性行為感染）診斷生態系統的採購、製造和分銷管道產生了累積影響。影響進口設備、套件和組件的關稅調整給供應鏈帶來了壓力，促使製造商和經銷商重新評估其籌資策略和庫存管理實踐。因此，實驗室、醫院和參考實驗室的採購團隊必須權衡確保持續獲得​​檢測的必要性與營運現實（例如前置作業時間波動和供應商談判）之間的關係。

為此，一些相關人員正在加快關鍵零件的在地採購，並在整個區域內尋找替代供應商，以降低貿易波動帶來的風險。這些調整也影響產品系列，開發商正在考慮儀器設計和耗材規格對跨境物流和監管合規性的影響。對於需要快速補貨的即時檢測機構和線上銷售管道就地檢驗，關稅引發的波動凸顯了與製造商和經銷商簽訂強力的分銷協議以及透明定價的重要性。

此外，關稅促使人們重新關注軟體和服務作為價值差異化因素，診斷設備供應商紛紛投資服務包，以減少終端用戶面臨的供應中斷風險。監管途徑和報銷談判必須與籌資策略同步調整，以確保患者能夠及時獲得檢測服務；相關人員也日益加強合作，制定合約保障措施和緊急時應對計畫，以保護常規篩檢和疫情應對能力。

綜合細分分析揭示了測試類型、最終用戶需求、產品形式、技術選擇、通路、目標疾病和檢體類型如何驅動策略重點。

詳細的細分分析揭示了性傳染性行為感染）檢測領域內產品開發、分銷和臨床應用在多個維度上的差異。就檢測類型而言，培養檢測在抗菌藥物敏感性試驗和確診流程中仍然至關重要，而瓊脂培養和細胞培養則繼續支持一些專業實驗室功能。核酸增幅檢查涵蓋了基於PCR的平台和等溫擴增方法。 PCR在靈敏檢測方面仍發揮核心作用，而等溫擴增方法則提供了更簡單快速的檢測方式，適用於分散式環境。快速檢測包括橫向流動化驗和照護現場平台，這些平台優先考慮速度和易用性，而酵素免疫分析法）和側向層析免疫檢測檢測則支持篩檢和流行病學監測。

終端使用者有著不同的操作需求：診斷和參考實驗室優先考慮的是通量、品管以及與實驗室資訊系統的整合；醫院和診所強調的是工作流程效率和臨床醫生可解讀性；而就地檢驗則重視易用性、快速結果報告和護理協調。產品類型也多種多樣，從注重耐用性和與各種耗材相容性的儀器，到需要穩定供應鏈保障和貨架穩定性的套件，再到能夠增強數據管理、結果報告和遠端患者互動的軟體和服務，不一而足。酵素免疫分析法）、等溫擴增、橫向流動化驗和聚合酶鍊式反應（PCR）等技術，都需要在靈敏度、特異性、成本和操作複雜性之間進行權衡。

通路（直銷、分銷商、線上通路）決定了市場覆蓋範圍和用戶支援模式，進而影響新檢測方法在臨床實踐中的普及速度。不同病原體的疾病特異性各不相同。披衣菌感染和淋病檢測通訊協定通常著重於核酸擴增方法，因為其診斷準確率高。皰疹檢測則根據臨床情況，結合直接檢測和血清學檢測。 HIV 檢測整合了快速篩檢和確診性分子檢測。梅毒診斷需要高靈敏度的血清學檢測和反射性檢測策略。檢體類型影響使用者體驗和接受度：血液和血清樣本是血清學檢測的標準樣本，尿液和拭子檢體是許多核酸檢測的首選樣本，而唾液檢體因其便捷的篩檢方式而日益普及。總而言之，這些細分因素共同影響著開發商和服務供應商的產品設計、監管策略和商業化路徑。

區域流行病學、法規環境、生產能力和分銷策略如何影響全球範圍內的普及和獲取差異

區域趨勢在流行病學、法規結構、生產能力和醫療服務模式等方面呈現出重要的背景差異，這些差異影響著檢測計畫的實施。在美洲，公共衛生篩檢計畫與積極的私部門參與和成熟的實驗室網路並存。就地檢驗和居家篩檢日益普及，這得歸功於數位化結果交付和廣泛的分銷管道。這些特點使得那些將強大的實驗室能力與以用戶為中心的設計以及與電子健康記錄和病例報告系統的高度整合相結合的解決方案更具優勢。

歐洲、中東和非洲地區（EMEA）的市場格局複雜多樣，包括嚴格的監管路徑、資源限制以及各國疾病流行率的波動。在此背景下，診斷試劑開發商必須權衡成本效益與嚴格的檢驗，並支援實驗室基礎設施的能力建設。與區域經銷商和公共衛生機構建立夥伴關係對於擴大產品覆蓋範圍和確保品質保證至關重要，尤其是在以參考實驗室和監測/疫情應對為重點的項目中。

亞太地區擁有眾多主要製造地，診斷測試應用迅速普及，尤其注重可擴展生產、行動醫療整合和線上分銷模式。大規模生產能力支持具有成本競爭力的套件製造，同時，對照護現場平台和遠端醫療服務的投資不斷增加，推動了對非侵入性採樣和快速結果交付的需求。在所有地區，協調監管申報、加強本地檢驗研究以及最佳化分銷策略對於確保產品部署與公共衛生目標和臨床工作流程保持一致至關重要。

競爭洞察著重分析技術差異化、夥伴關係、監管策略和服務導向模式對市場定位和市場接受度的影響。

性行為感染感染診斷領域的競爭是由技術差異化、策略聯盟以及超越核心檢測能力的增值服務共同驅動的。主要企業正致力於提升分析靈敏度和特異性，同時透過簡化工作流程和整合數位化報告來最佳化使用者體驗。這種組合支援在中心實驗室和患者床邊等多種環境中部署，為那些能夠證明產品具有實際效用和完善品質系統的企業創造了機會。

隨著越來越多的公司尋求加速市場准入並縮短臨床應用時間，設備製造商、套件供應商和分銷合作夥伴之間的策略聯盟日益普遍。此外，將診斷設備與軟體和服務（例如連接解決方案、培訓和售後支援）結合的公司，透過解決醫院、診所和照護現場機構面臨的應用障礙，正在獲得競爭優勢。圍繞新型擴增化學和多重檢測方法的智慧財產權仍然是區分企業的關鍵因素，在多個司法管轄區獲得監管批准的能力也同樣重要。

市場相關人員也在探索差異化的商業模式，包括基於訂閱的設備和耗材使用方式、涵蓋品管和培訓的綜合服務協議，以及針對公共衛生客戶的、強調經濟性和規模化的項目。這些方法反映出一種更廣泛的趨勢，即解決方案應將產品性能與實際實施支援相結合，以促進永續應用。

經營團隊可採取的策略重點，包括加強供應鏈韌性、加簡介護現場、整合數位化工作流程以及與監管機構和公共衛生合作夥伴合作。

產業領導者應採取能夠增強韌性、加快普及速度並最大限度地提升不同醫療環境下臨床應用效果的策略。優先考慮供應鏈多元化和關鍵零件的多通路採購，可降低貿易中斷和關稅風險；同時，投資本地製造和組裝，可縮短前置作業時間並有助於合規。此外，加速利用等溫擴增技術和改進的側向流動化學方法開發就地檢驗和快速檢測，可擴大其在社區和分散式醫療機構的應用範圍，使患者能夠即時獲得檢測結果並及時接受治療和通知合作夥伴。

領導者還應加強數位化整合，將連接性、自動化報告和決策支援功能融入其檢測平台和服務產品中。這種整合將改善監測，簡化個案管理，並增強對醫院和公共衛生合作夥伴的價值提案。在商業性，透過採用全通路分銷策略，結合面向大型機構客戶的直接銷售、用於本地滲透的經銷商應對力以及面向更廣泛消費者的線上管道，可以最佳化市場涵蓋範圍和響應速度。

最後，各機構應積極與監管機構和公共衛生利益相關人員合作，簡化檢驗流程，參與合作研究以證明其在不同人群中的臨床效用，並設計定價和准入方案，以減少高需求社區的就醫障礙。技術創新，結合切實可行的部署策略和相關人員的協作，可以持續改善檢測覆蓋率和臨床療效。

對用於得出研究結果的方法的透明度（關於主要訪談、次要證據綜合、細分分析和品質保證通訊協定的詳細資訊）

本報告的研究採用了一種綜合性的混合方法，以確保分析的嚴謹性、情境有效性和可重複性。主要研究包括對臨床實驗室主任、照護現場專案經理、採購負責人和監管專家進行結構化訪談，以了解營運限制、實施促進因素和採購考量。此外，還與診斷設備開發商和分銷合作夥伴進行了討論，以了解他們的產品開發藍圖和分銷策略。

二次研究包括對同行評審文獻、監管指導文件、白皮書和已發布的技術規範進行系統性回顧，以檢驗性能特徵和技術屬性。採用資料三角驗證法，將主要訪談結果與已記錄的證據進行交叉比對，以確保定性和定量指標的一致性。按測試類型、最終用戶群、產品類型、技術、分銷管道、疾病目標和檢體類型進行細分分析，從而為開發人員和採購人員提供可操作的見解。

品質保證通訊協定包括對訪談結果進行交叉檢驗、反覆的專家評審以及對假設和局限性的透明記錄。整個過程均遵循訪談知情同意和資料處理的倫理標準。調查方法強調基於現有證據的分析，避免推測性預測，並著重於經驗因素和對相關人員的實際意義。

這份簡明扼要的摘要重點闡述了創新、營運韌性和跨部門合作將如何影響性傳染病檢測的提供和取得方式。

摘要，目前性行為感染檢測領域呈現出技術進步與實施複雜性並存的局面。核酸擴增技術、照護現場平台和非侵入性採樣技術的進步雖然拓展了診斷能力，但供應鏈韌性、監管差異和物流配送等實際操作問題仍然限制這些技術的應用。那些能夠使產品設計與終端用戶工作流程相契合、投資於數位連接並積極管理採購風險的相關人員，將更有能力把創新轉化為更佳的臨床療效。

區域差異凸顯了製定客製化策略的重要性，例如在亞太地區充分利用其製造優勢和線上管道，在歐洲、中東和非洲與監管機構和公共衛生機構建立合作關係，以及在美洲整合照護現場和居家檢測模式。考慮疾病的具體需求和檢體類型將進一步縮小部署方案的選擇範圍，並指南多重檢測、血清學平台或基於培養的確認檢測哪種方式最為理想。最終，製造商、實驗室、臨床醫生、支付方和公共衛生機構之間的跨部門合作對於擴大有效且公平的檢測項目規模至關重要。

展望未來，對品質、互通性和相關人員參與的嚴格把控將決定哪些創新能夠永續地融入臨床實踐。透過專注於務實的實施和穩健的商業策略，該領域可以擴大高品質檢測的覆蓋範圍，並加強對性行為感染影響的個人和社區的持續護理。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 消費者對可當日出結果且具有更高隱私保護功能的家用多重檢測套組的需求日益成長。
  • 拓展遠端醫療平台，提供結合性傳染病篩檢的虛擬諮詢服務
  • 整合人工智慧（AI）驅動的診斷技術，以提高性行為感染傳染病檢測工作流程的準確性和速度
  • 透過藥局和診所合作提供快速性行為感染傳染病檢測服務
  • 消費者擴大接受基於訂閱的性健康服務，並定期進行性行為感染監測
  • 利用區塊鏈技術保護病患資料並增強性行為感染傳染病檢測報告的隱私性
  • 針對服務不足社區的行動偵測車的出現，使得按需進行性行為感染篩檢和治療成為可能。
  • 監管部門核准將促進披衣菌感染、淋病和其他性行為感染傳染病多重快速檢測的廣泛應用
  • 智慧型手機連接診斷設備的開發使得性行為感染傳染病檢測結果的即時傳輸和追蹤成為可能。
  • 加強對性行為感染傳染病檢測中抗菌素抗藥性監測的重視，以指南標靶治療通訊協定

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章性行為感染傳染病檢測市場（依檢測類型分類）

  • 培養試驗
    • 瓊脂培養基培養法
    • 細胞培養
  • 核酸增幅檢查
    • 等溫擴增
    • 基於PCR的
  • 快速檢測
    • 橫向流動化驗
    • 照護現場平台
  • 血清學檢測
    • 酵素免疫分析法
    • 橫向流動化驗

第9章性行為感染傳染病檢測市場（依最終用戶分類）

  • 診斷實驗室
  • 醫院和診所
  • 即時偵測設施
  • 參考實驗室

第10章性行為感染傳染病檢測市場（依產品分類）

  • 裝置
  • 套件
  • 軟體和服務

第11章 按技術分類的性行為感染傳染病檢測市場

  • 酵素免疫分析法
  • 等溫擴增
  • 橫向流動化驗
  • 基於PCR的

第12章性行為感染傳染病檢測市場（依通路分類）

  • 直銷
  • 批發商
  • 線上管道

第13章性行為感染傳染病檢測市場（依疾病類型分類）

  • 披衣菌感染
  • 淋病
  • 皰疹
  • HIV
  • 梅毒

第14章 依檢體類型分類的性行為感染傳染病檢測市場

  • 血
  • 唾液
  • 拭子
  • 尿

第15章 各地區性行為感染傳染病檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章性行為感染傳染病檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國性行為感染傳染病檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Laboratory Corporation of America Holdings
    • Quest Diagnostics Incorporated
    • Hologic, Inc.
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Danaher Corporation
    • Becton Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • OraSure Technologies, Inc.
    • Quidel Corporation
Product Code: MRR-69324464D0F2

The STD Testing Market is projected to grow by USD 16.03 billion at a CAGR of 6.11% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.97 billion
Estimated Year [2025] USD 10.58 billion
Forecast Year [2032] USD 16.03 billion
CAGR (%) 6.11%

An authoritative orientation to the current sexually transmitted disease testing environment shaped by innovation, access pressures, and evolving care delivery models

The landscape of sexually transmitted disease testing is undergoing rapid and sustained transformation as technological advances converge with shifting policy priorities and evolving patterns of care delivery. Public health programs, clinical laboratories, and point-of-care providers are responding to rising demand for faster, more accurate, and accessible diagnostics while confronting persistent barriers such as stigma, inconsistent reimbursement, and variable regulatory environments. These tensions are reshaping how tests are developed, validated, and delivered across multiple settings, from centralized reference laboratories to decentralized point-of-care locations.

Diagnostics developers and health systems are prioritizing innovations that reduce time to result, expand non-invasive sampling, and enable multiplexed detection of pathogens to streamline clinical decision-making. At the same time, digital health integration and software-enabled workflows are improving data capture, reporting, and patient linkage to care. As a result, stakeholders across the value chain are increasingly focused on interoperability, quality assurance, and the practicalities of scaling novel testing modalities in diverse clinical and community contexts.

To navigate this environment, leaders must interpret technical advances in the context of operational realities and regulatory constraints while preserving equitable access. The following sections unpack the transformative shifts, tariff-related impacts, segmentation insights, and region-specific considerations that collectively define the current moment for STD testing.

How innovations in molecular methods, non-invasive sampling, digital integration, and distribution models are reshaping STD testing delivery and clinical decision-making

The field has experienced several transformative shifts that are altering clinical pathways, supply chains, and patient experiences. First, molecular diagnostics have migrated from specialized laboratories to near-patient settings through simplified workflows and robust sample-to-answer platforms, enabling nucleic acid amplification technologies to drive earlier and more reliable detection. Concurrently, advances in isothermal amplification techniques and improvements in lateral flow assay chemistry have narrowed performance gaps between rapid tests and laboratory-based assays, expanding options for immediate decision-making at the point of care.

Second, the expansion of non-invasive sample types such as saliva and self-collected swabs is lowering barriers to testing and enabling broader screening initiatives outside traditional clinical settings. This shift is complemented by software and services that support remote result delivery, patient follow-up, and electronic case reporting, creating more integrated care pathways. Third, distribution and procurement channels have diversified as manufacturers and distributors adopt omnichannel strategies, including direct sales, distributor networks, and online platforms that reach community-based organizations and home-testing consumers.

Finally, regulatory modernization and public health priorities have encouraged adaptive study designs and accelerated pathways for clinically-validated assays, while emerging attention to antimicrobial resistance underscores the need for diagnostics that inform treatment selection. Together, these shifts demand coordinated responses from developers, laboratories, and health authorities to ensure diagnostic performance, equitable access, and sustainability of testing programs.

Evaluating the cumulative supply chain and procurement consequences of 2025 tariff shifts on diagnostics instruments, kits, and end-user resilience across the testing ecosystem

Recent trade policy changes introduced in 2025 have produced cumulative effects across procurement, manufacturing, and distribution channels that serve the sexually transmitted disease diagnostics ecosystem. Tariff adjustments impacting imported instruments, kits, and component parts have pressured supply chains, prompting manufacturers and distributors to reassess sourcing strategies and inventory management practices. As a consequence, procurement teams in diagnostic laboratories, hospitals, and reference centers have had to balance the imperative for uninterrupted testing access with the operational realities of lead-time variability and supplier negotiation.

In response, some stakeholders have accelerated localization efforts for critical components and explored alternative suppliers across regions to reduce exposure to trade-related volatility. These adjustments have implications for product portfolios, as developers consider how instrument designs and consumable formats influence cross-border logistics and regulatory compliance. For point-of-care testing sites and online channels that rely on rapid replenishment, the tariff-driven dynamics have highlighted the importance of resilient distribution agreements and transparent pricing arrangements with manufacturers and distributors.

Moreover, tariffs have catalyzed renewed emphasis on software and services as value differentiators, with diagnostics providers investing in service packages that mitigate supply disruptions for end users. Regulatory pathways and reimbursement conversations must adapt alongside procurement strategies to preserve patient access to timely testing, and stakeholders are increasingly collaborating on contractual safeguards and contingency plans that protect routine screening and outbreak response capabilities.

Integrated segmentation analysis explains how test type, end-user needs, product form factors, technology selection, distribution channels, disease targets, and sample types drive strategic priorities

A granular view of segmentation reveals how product development, distribution, and clinical adoption vary across multiple dimensions of the STD testing landscape. When considering test type, culture tests remain relevant for antimicrobial susceptibility and confirmatory workflows, with agar-based culture and cell culture continuing to support specialized laboratory functions. Nucleic acid amplification tests encompass both PCR-based platforms and isothermal amplification methods; PCR maintains a central role for high-sensitivity detection while isothermal approaches enable simplified, rapid formats suited to decentralized settings. Rapid tests include lateral flow assays and point-of-care platforms that prioritize speed and ease of use, whereas serology testing through enzyme immunoassays and lateral flow immunoassays supports screening and epidemiological surveillance.

End users exhibit distinct operational requirements: diagnostic laboratories and reference laboratories prioritize throughput, quality control, and integration into laboratory information systems, hospitals and clinics focus on workflow efficiency and clinician-facing interpretability, and point-of-care testing sites emphasize ease of use, rapid turnaround, and linkage to care. Product types span instruments, where durability and compatibility with diverse consumables matter, kits that demand consistent supply chain assurance and shelf stability, and software and services that enhance data management, result reporting, and remote patient engagement. Technologies such as enzyme immunoassay, isothermal amplification, lateral flow assay, and PCR each present trade-offs between sensitivity, specificity, cost, and operational complexity.

Distribution channels-direct sales, distributors, and online channels-shape market reach and user support models, influencing how quickly new assays penetrate clinical practice. Disease-specific dynamics vary by pathogen: chlamydia and gonorrhea testing protocols often emphasize nucleic acid amplification for high diagnostic accuracy, herpes relies on a combination of direct detection and serology depending on clinical context, HIV testing integrates both rapid screening and confirmatory molecular assays, and syphilis diagnostics require sensitive serology with reflex testing strategies. Sample types influence user experience and adoption, with blood and serum samples remaining standard for serology, urine and swab specimens favored for many nucleic acid assays, and saliva increasingly used for user-friendly screening initiatives. Collectively, these segmentation layers inform product design, regulatory strategy, and commercialization pathways for developers and service providers.

How regional epidemiology, regulatory ecosystems, manufacturing capability, and distribution strategies shape differential adoption and access across global regions

Regional dynamics introduce critical contextual differences in epidemiology, regulatory frameworks, manufacturing capacity, and care delivery models that shape testing program implementation. In the Americas, substantial private sector participation and established laboratory networks coexist with active public health screening programs; the region shows strong uptake of point-of-care testing and home-based screening, supported by digital result delivery and broad distribution channels. These dynamics favor solutions that combine robust laboratory performance with user-focused design and strong connectivity to electronic health records and case reporting systems.

Europe, Middle East & Africa presents a heterogenous landscape characterized by stringent regulatory pathways in some markets, resource constraints in others, and variable disease prevalence across countries. Here, diagnostics developers must balance cost-effectiveness with rigorous validation and support capacity building for laboratory infrastructure. Partnerships with regional distributors and public health agencies are pivotal to expanding access and ensuring quality assurance, particularly for reference laboratories and programs focused on surveillance and outbreak response.

Asia-Pacific encompasses major manufacturing hubs and rapidly expanding diagnostic adoption, with a strong emphasis on scalable production, mobile health integration, and online distribution models. High-volume manufacturing capacity supports cost-competitive kit production, while rising investments in point-of-care platforms and telehealth services drive demand for non-invasive sampling and rapid result delivery. Across all regions, harmonizing regulatory submissions, strengthening local validation studies, and tailoring distribution strategies are essential to align product deployment with public health goals and clinical workflows.

Competitive landscape insights highlighting how technological differentiation, partnerships, regulatory strategy, and service-oriented models influence market positioning and adoption

Competitive dynamics in the STD diagnostics space are shaped by a mix of technological differentiation, strategic partnerships, and service-based offerings that extend beyond core assay performance. Leading developers are investing in features that improve analytical sensitivity and specificity while optimizing user experience through simplified workflows and integrated digital reporting. This combination supports adoption in both centralized laboratories and near-patient environments, creating opportunities for companies that can demonstrate real-world utility and robust quality systems.

Strategic alliances between instrument manufacturers, kit suppliers, and distribution partners are increasingly common as companies seek to accelerate market access and reduce time-to-adoption in clinical settings. Additionally, firms that pair diagnostics with software and services-such as connectivity solutions, training, and after-sales support-gain competitive advantage by addressing implementation barriers faced by hospitals, clinics, and point-of-care providers. Intellectual property around novel amplification chemistries and multiplexing approaches remains a differentiator, as does the ability to secure regulatory clearances across multiple jurisdictions.

Market actors are also exploring differentiated commercial models, including subscription-based access to instruments and consumables, bundled service agreements that include quality control and training, and targeted programs for public health customers that emphasize affordability and scale. These approaches reflect a broader pivot toward solutions that integrate product performance with practical deployment support to drive sustainable uptake.

Actionable strategic priorities for executives to strengthen supply resilience, accelerate point-of-care uptake, integrate digital workflows, and collaborate with regulators and public health partners

Industry leaders should pursue strategies that enhance resilience, accelerate access, and maximize clinical impact across diverse care settings. Prioritizing supply chain diversification and dual-source procurement for critical components will reduce exposure to trade disruptions and tariffs while investments in localized manufacturing or regional assembly can shorten lead times and support regulatory alignment. Concurrently, accelerating development of point-of-care and rapid testing modalities that leverage isothermal amplification and improved lateral flow chemistries will expand reach into community and decentralized settings where immediate results facilitate timely treatment and partner notification.

Leaders should also strengthen digital integration by embedding connectivity, automated reporting, and decision-support capabilities into test platforms and service offerings. This integration improves surveillance, simplifies case management, and enhances the value proposition for hospitals and public health partners. Commercially, adopting omnichannel distribution strategies-combining direct sales for large institutional customers, distributor relationships for regional penetration, and online channels for broader consumer access-will optimize market reach and responsiveness.

Finally, organizations should engage proactively with regulators and public health stakeholders to streamline validation pathways, participate in collaborative studies that demonstrate clinical utility across diverse populations, and design pricing and access programs that reduce barriers for high-need communities. By coupling technological innovation with pragmatic deployment strategies and stakeholder engagement, firms can drive sustainable improvements in testing coverage and clinical outcomes.

Methodological transparency detailing primary interviews, secondary evidence synthesis, segmentation analysis, and quality assurance protocols used to derive research findings

The research underpinning this report employed a comprehensive mixed-methods approach designed to ensure analytical rigor, contextual relevance, and reproducibility. Primary research included structured interviews with clinical laboratory directors, point-of-care program managers, procurement officers, and regulatory specialists to capture operational constraints, adoption drivers, and procurement considerations. These interviews were supplemented by consultations with diagnostic developers and distribution partners to understand product development roadmaps and channel strategies.

Secondary research encompassed systematic review of peer-reviewed literature, regulatory guidance documents, white papers, and publicly available technical specifications to validate performance characteristics and technology attributes. Data triangulation methods were applied to reconcile insights from primary interviews with documented evidence, ensuring consistency across qualitative and quantitative indicators. Segmentation analysis was performed across test type, end-user category, product typology, technology, distribution channel, disease target, and sample type to derive actionable insights for developers and purchasers.

Quality assurance protocols included cross-validation of interview findings, iterative review cycles with subject-matter experts, and transparent documentation of assumptions and limitations. Ethical standards for interview consent and data handling were observed throughout. While the methodology emphasizes current, evidence-based analysis, the report avoids speculative forecasting and instead focuses on empirical drivers and pragmatic implications for stakeholders.

A concise synthesis emphasizing how innovation, operational resilience, and cross-sector collaboration determine the trajectory of STD testing implementation and access

In synthesis, the current STD testing landscape reflects a balance between technological progress and implementation complexity. Advances in nucleic acid amplification, point-of-care platforms, and non-invasive sampling are expanding diagnostic capabilities, yet operational realities such as supply chain resilience, regulatory variability, and distribution logistics continue to temper adoption pathways. Stakeholders who align product design with end-user workflows, invest in digital connectivity, and proactively manage procurement risks will be better positioned to translate innovation into improved clinical outcomes.

Regional differences underscore the importance of tailored strategies, whether that means leveraging manufacturing strengths and online channels in Asia-Pacific, navigating regulatory and public health partnerships in Europe, Middle East & Africa, or integrating point-of-care and home-testing models across the Americas. Disease-specific needs and sample type considerations further refine deployment choices, informing where multiplex assays, serology platforms, or culture-based confirmation remain most appropriate. Ultimately, cross-sector collaboration among manufacturers, laboratories, clinicians, payers, and public health authorities is essential to scale testing programs that are both effective and equitable.

Moving forward, disciplined attention to quality, interoperability, and stakeholder engagement will determine which innovations achieve sustainable integration into clinical practice. By focusing on pragmatic implementation and resilient commercial strategies, the sector can expand access to high-quality testing and strengthen the continuum of care for individuals and communities affected by sexually transmitted infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing demand for at home multiplex STD testing kits with same day results and increased privacy
  • 5.2. Expansion of telemedicine platforms offering virtual consultations alongside STD screening
  • 5.3. Integration of AI driven diagnostics to improve accuracy and speed of STD detection workflows
  • 5.4. Partnerships between pharmacies and health clinics to provide point of care rapid STD testing services
  • 5.5. Rising consumer adoption of subscription based sexual health services with regular STD monitoring
  • 5.6. Implementation of blockchain technology to secure patient data and enhance privacy in STD test reporting
  • 5.7. Emergence of mobile testing vans targeting underserved communities for on demand STD screening and treatment
  • 5.8. Regulatory approvals accelerating the availability of multiplex rapid tests for chlamydia gonorrhea and other STDs
  • 5.9. Development of smartphone integrated diagnostic devices enabling instant STD result transmission and tracking
  • 5.10. Increased focus on antimicrobial resistance surveillance in STD testing to guide targeted treatment protocols

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. STD Testing Market, by Test Type

  • 8.1. Culture Tests
    • 8.1.1. Agar Based Culture
    • 8.1.2. Cell Culture
  • 8.2. Nucleic Acid Amplification Tests
    • 8.2.1. Isothermal Amplification
    • 8.2.2. PCR Based
  • 8.3. Rapid Tests
    • 8.3.1. Lateral Flow Assays
    • 8.3.2. Point Of Care Platforms
  • 8.4. Serology Tests
    • 8.4.1. Enzyme Immunoassay
    • 8.4.2. Lateral Flow Assays

9. STD Testing Market, by End User

  • 9.1. Diagnostic Laboratories
  • 9.2. Hospitals And Clinics
  • 9.3. Point Of Care Testing Sites
  • 9.4. Reference Laboratories

10. STD Testing Market, by Product

  • 10.1. Instruments
  • 10.2. Kits
  • 10.3. Software And Services

11. STD Testing Market, by Technology

  • 11.1. Enzyme Immunoassay
  • 11.2. Isothermal Amplification
  • 11.3. Lateral Flow Assay
  • 11.4. PCR Based

12. STD Testing Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors
  • 12.3. Online Channels

13. STD Testing Market, by Disease Type

  • 13.1. Chlamydia
  • 13.2. Gonorrhea
  • 13.3. Herpes
  • 13.4. HIV
  • 13.5. Syphilis

14. STD Testing Market, by Sample Type

  • 14.1. Blood
  • 14.2. Saliva
  • 14.3. Swab
  • 14.4. Urine

15. STD Testing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. STD Testing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. STD Testing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Laboratory Corporation of America Holdings
    • 18.3.2. Quest Diagnostics Incorporated
    • 18.3.3. Hologic, Inc.
    • 18.3.4. F. Hoffmann-La Roche AG
    • 18.3.5. Abbott Laboratories
    • 18.3.6. Danaher Corporation
    • 18.3.7. Becton Dickinson and Company
    • 18.3.8. Bio-Rad Laboratories, Inc.
    • 18.3.9. OraSure Technologies, Inc.
    • 18.3.10. Quidel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS STD TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL STD TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. STD TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. STD TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. STD TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL STD TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL STD TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS STD TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS STD TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE STD TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE STD TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPE STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPE STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPE STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPE STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPE STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 343. EUROPE STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 344. EUROPE STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 345. EUROPE STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 346. EUROPE STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 347. EUROPE STD TESTING MARKET SIZ